CymaBay Therapeutics (NASDAQ:CBAY)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Wednesday, MarketBeat reports. They presently have a $18.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $12.00. HC Wainwright’s price objective suggests a potential upside of 54.64% from the company’s current price.
Other research analysts have also recently issued research reports about the company. Leerink Swann reaffirmed a “buy” rating and set a $16.00 target price on shares of CymaBay Therapeutics in a research note on Tuesday, November 28th. Oppenheimer set a $15.00 price objective on CymaBay Therapeutics and gave the stock a “buy” rating in a research note on Monday, October 30th. Cantor Fitzgerald reissued a “buy” rating and issued a $16.00 price objective on shares of CymaBay Therapeutics in a research note on Wednesday, November 8th. Zacks Investment Research cut CymaBay Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, January 16th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $12.00 price objective on shares of CymaBay Therapeutics in a research note on Friday, October 27th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. CymaBay Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $16.56.
CymaBay Therapeutics (NASDAQ CBAY) traded down $0.20 on Wednesday, hitting $11.64. The stock had a trading volume of 622,862 shares, compared to its average volume of 626,488. The company has a market capitalization of $510.58, a PE ratio of -11.52 and a beta of 1.82. CymaBay Therapeutics has a 1 year low of $1.60 and a 1 year high of $12.33. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.39 and a current ratio of 7.39.
In other CymaBay Therapeutics news, Director Kurt Von Emster sold 39,438 shares of the company’s stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $12.18, for a total transaction of $480,354.84. Following the completion of the sale, the director now owns 90,000 shares in the company, valued at $1,096,200. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Charles Mcwherter bought 5,000 shares of the stock in a transaction on Thursday, November 2nd. The shares were bought at an average price of $8.67 per share, with a total value of $43,350.00. Following the acquisition, the senior vice president now owns 10,300 shares of the company’s stock, valued at $89,301. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 626,656 shares of company stock valued at $6,238,232. 15.10% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of the business. Perceptive Advisors LLC purchased a new stake in shares of CymaBay Therapeutics during the 3rd quarter valued at $18,948,000. Citadel Advisors LLC acquired a new position in shares of CymaBay Therapeutics in the 3rd quarter valued at $5,159,000. EAM Investors LLC acquired a new position in shares of CymaBay Therapeutics in the 3rd quarter valued at $4,788,000. Omega Fund Management LLC increased its position in shares of CymaBay Therapeutics by 82.9% in the 3rd quarter. Omega Fund Management LLC now owns 551,477 shares of the biopharmaceutical company’s stock valued at $4,445,000 after acquiring an additional 250,000 shares during the period. Finally, Ameriprise Financial Inc. acquired a new position in shares of CymaBay Therapeutics in the 3rd quarter valued at $1,536,000. Institutional investors own 69.12% of the company’s stock.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.